#PharmaTimes #pharma #pharmaceuticals #Brensocatib #Brinsupri #noncysticfibrosisbronchiectasis #MHRA #MedicinesandHealthcareproductsRegulatoryAgency #marketingauthorisation #chroniccondition #dipeptidylpeptidase1 #inflammatoryprocess #lungs #respiratory #JulianBeach
zurl.co/LPYPc
zurl.co/LPYPc
Brensocatib becomes first licensed treatment for non‑cystic fibrosis bronchiectasis - PharmaTimes
MHRA authorises medicine for patients aged 12 and over with repeated flare‑ups
pharmatimes.com
February 26, 2026 at 10:15 AM